Sanofi Loses Bid To Stay Launch Of Generic Eloxatin

Law360, New York (July 6, 2009, 12:00 AM EDT) -- A judge has denied Sanofi-Aventis US LLC's request to stay the launch of generic versions of its popular colon cancer drug Eloxatin pending appeal of a finding of noninfringement in Sanofi's suit against Sandoz Inc., Teva Pharmaceutical Industries Ltd. and others.

Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Wednesday ruled that granting Sanofi's request would be “unwarranted.”

The judge determined that the plaintiffs' arguments on appeal were similar to those raised when he addressed the underlying summary judgment...
To view the full article, register now.